15 To 23 Amino Acid Residues In Defined Sequence Patents (Class 530/326)
  • Patent number: 11065307
    Abstract: Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: July 20, 2021
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Michael F. Concino, Pericles Calias, Jing Pan, Kevin Holmes, Paolo Martini, Alla Romashko, Muthuraman Meiyappan, Bohong Zhang, Andrea Iskenderian, Dianna Lundberg, Angela Norton, Bettina Strack-Logue, Huang Yan, Mary Alessandrini, Richard Pfeifer
  • Patent number: 11054417
    Abstract: For fluorescent nanoparticles having a zeta potential of ?10 mV to ?60 mV at pH 7.0 or a zeta potential of 0 mV to ?10 mV in a buffer of pH 6.0 to 8.0, an appropriate electrical repulsive force can be generated between biomolecules that are generally negatively charged and the fluorescent nanoparticles. As a result, non-specific binding between the fluorescent nanoparticles and the biomolecules is suppressed and the fluorescent nanoparticles are specifically bound to a biomolecule to be stained through interaction stronger than the electrical repulsive force, so that the visibility of the specific biomolecule to be stained can be improved. Further, since an appropriate electrical repulsive force is also generated between the fluorescent nanoparticles themselves, aggregation of the fluorescent nanoparticles can be inhibited and the dispersibility in a staining solution can thereby be maintained.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: July 6, 2021
    Assignee: KONICA MINOLTA, INC.
    Inventors: Hideki Gouda, Masaru Takahashi, Kensaku Takanashi, Fuminori Okada
  • Patent number: 11014981
    Abstract: Provided are a method for preparing a new type of recombinant anti-TNF-? chimeric monoclonal antibody and a use. The method comprises: designing and synthesizing the light chain and heavy chain of a CMAB008 antibody according to the preferred codon of a hamster; constructing a eukaryotic expression vector; transfecting an CHO-CR-GS ?/? host cell with a GS knockout; and cultivating the cell using a serum-free culture technique; isolating and purifying; and thereby obtaining a low immunogenic CMAB008 antibody.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: May 25, 2021
    Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.
    Inventor: Weizhu Qian
  • Patent number: 10941179
    Abstract: The present invention relates to a method for suppressing aggregation of polypeptide. Specifically, the present invention relates to a method for suppressing, in a solution comprising an antibody or an Fc region-containing protein, formation of an aggregate derived from an antibody or an Fc region-containing protein having a non-native conformation, the method comprising: the steps of (i) binding an AF.2A1 polypeptide or an analog thereof with an aggregate derived from the antibody or Fc region-containing protein having a non-native conformation in the solution; and (ii) collecting the aggregate bound to the polypeptide or analog thereof from the solution.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: March 9, 2021
    Inventors: Yukako Senga, Hideki Watanabe, Shinya Honda
  • Patent number: 10792327
    Abstract: Provided herein are glycosylated peptide amphiphiles (GPAs), supramolecular glyconanostructures assembled therefrom, and methods of use thereof. In particular, provided herein are glycosaminoglycan (GAG) mimetic peptide amphiphiles (PAs) and supramolecular GAG mimetic nanostructures assembled therefrom that mimic the biological activities of GAGs, such as heparin, heparan sulfate, hyaluronic acid etc.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: October 6, 2020
    Assignee: Northwestern University
    Inventors: Samuel I. Stupp, Bo Timmy Bjorn Fyrner, Sung Soo Lee
  • Patent number: 10786548
    Abstract: The teachings generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?v?3 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: September 29, 2020
    Inventor: Xiadong Feng
  • Patent number: 10744078
    Abstract: Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations are designed for topical application onto the skin of a patient and may be used to treat wrinkles, hyperhidrosis, and other health-related problems. Kits for administration are also described.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: August 18, 2020
    Inventors: Michael D Dake, Jacob M Waugh
  • Patent number: 10729741
    Abstract: A treatment window for the intravenous treatment of wounds, including thermal and chemical burns, with cP12 is presented. In particular, Applicants have unexpectedly found that delaying intravenous treatment with fibronectin-derived peptides, such as cP12, from 2 to 6 hours, particularly about 4 hours, after wounding, provides superior wound-closing results than treatment at 1 hour or after 8 or more hours.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: August 4, 2020
    Assignee: NeoMatrix Therapeutics Inc.
    Inventors: Richard August Clark, Fubao Lin
  • Patent number: 10723764
    Abstract: Anti-microbial peptides and methods of use are provided.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: July 28, 2020
    Inventor: Guangshun Wang
  • Patent number: 10689418
    Abstract: The invention provides a series of peptides with N-methyl-D-aspartate (NMDA) receptor modulating activity. Specifically it contains two synthetic peptides acting as ion inflow antagonists through the NMDA receptor with specificity GluN2B and GluN2A NMDA receptor subunits and a peptide having agonist activity regarding the NMDA receptor in rat hippocampal neuron cultures.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 23, 2020
    Assignee: Universidad Nacional de Colombia
    Inventors: Edgar Antonio Reyes Montaño, Edwin Alfredo Reyes Guzmán, Nohora Angélica Vega Castro
  • Patent number: 10604537
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: March 31, 2020
    Inventors: Martin Valik, Roman Gabriel, Pavel Vraspir, David Lukas
  • Patent number: 10570371
    Abstract: Provided is a method for isolating and proliferating autologous cancer antigen-specific CD8+ T cells, and more particularly, a method for selecting an epitope recognized by CD8+ T cells from autologous cancer antigens present in blood of individual cancer patients; and isolating autologous cancer antigen-specific CD8+ T cells by using a peptide of the selected epitope, and a method of massively proliferating CD8+ T cells by using the method. According to the present invention, it is possible to isolate autologous cancer antigen-specific CD8+ T cells by using the peptide of the CD8 T cell epitope of the autologous cancer antigen present in blood of individual cancer patients instead of a heterologous antigen. Therefore, by using T cells recognizing the autologous cancer antigen, it is possible to effectively select and eliminate cancer cells derived from the cancer patient's own cells. Thus, T cells can be applied to treatment and alleviation of cancer diseases without side effects.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: February 25, 2020
    Assignee: Eutilex Co., Ltd.
    Inventors: Byoung S. Kwon, Hyun-Guy Kang, Kwang-Hui Kim, Young-Woo Kim, Young Ho Kim, Byung-Kiu Park, Sang-Yoon Park, Sang-Jae Park, Hyeon-Seok Eom, Ho-Sik Oh, Heon Yoo, Don-Gil Lee, Seung-Hoon Lee, Young-Joo Lee, Jin-Soo Lee, Beom-Kyu Choi
  • Patent number: 10201587
    Abstract: The present invention is directed to methods of inhibition, delay of formation, treatment, prophylaxis and/or prevention of infections caused by bacteria that exhibit tolerance to antimicrobial agents, including slow growing, stationary-phase and biofilm forming bacteria, through the use of glycopeptide antibiotics, such as oritavancin.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: February 12, 2019
    Inventors: Eve Neesham-Grenon, Gregory Moeck, Adam Belley, Thomas R. Parr, Jr., Adel Rafai Far
  • Patent number: 10131698
    Abstract: Anti-microbial compositions comprising synthetic peptides for therapeutic use are described. These compositions have found applications in treating human and plant infections.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: November 20, 2018
    Assignee: Council of Scientific & Industrial Research
    Inventors: Shuchishweta Vinay Kendurkar, Durba Sengupta
  • Patent number: 9994858
    Abstract: The present invention relates generally to constructs and their use in gene expression or gene regulation assays. More particularly, the present invention provides expression vectors and/or reporter vectors providing kinetics of protein expression with improved temporal correlation to promoter activity. Even more particularly, the invention provides expression vectors comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding a RNA element that modulates the stability of a transcript corresponding to the transcribable polynucleotide. The present invention provides, inter alia, novel vectors, useful for identifying and analysing cis- and trans-acting regulatory sequences/factors as well as vectors and genetically modified cell lines or organisms that are particularly useful for drug screening and drug discovery.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: June 12, 2018
    Assignee: Gene Stream PTY LTD
    Inventor: John Daly
  • Patent number: 9975933
    Abstract: A tumor tissue-penetrating peptide specifically binding to neuropilin, or a fusion protein, a small molecule drug, a nanoparticle, or a liposome having the peptide fused therein is provided, as well as a method for preparing the same and a pharmaceutical composition comprising the same for treating, diagnosing, or preventing cancer or angiogenesis-related diseases. The tumor tissue-penetrating peptide is fused to the C-terminus of an anticancer antibody heavy-chain constant region (Fc) and the fused antibody specifically binds to neuropilin, and specifically accumulates in tumor tissue, widens intercellular gaps between tumor vascular endothelial cells, promotes extravasation, increases infiltration within tumor tissue, and shows a remarkably increased in vivo tumor-suppressing activity.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: May 22, 2018
    Inventors: Yong Sung Kim, Tae Hwan Shin, Yae Jin Kim, Eun Sil Sung
  • Patent number: 9932384
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: April 3, 2018
    Assignee: immatics biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 9907837
    Abstract: The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: March 6, 2018
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 9814734
    Abstract: The present invention provides a bufalin liposome comprising a liposome bilayer and bufalin. The liposome bilayer comprises phospholipid, sterol and polyethylene glycol (PEG)-derived compound. The liposome of the present invention can be used to treat cancer, especially a cancer chosen from liver cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, pancreas cancer, gastric cancer, and leukemia. The preparation method of the present invention is simple, and the bufalin liposome can increase an effect of antitumor, reduce a toxicity compared with bufalin monomer, and has wide applications.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: November 14, 2017
    Assignee: The Fourth Military Medical University
    Inventors: Wei Cao, Siwang Wang, Ying Li, Yanhua Xie, Qian Yang
  • Patent number: 9751919
    Abstract: Compositions and methods for the treatment of antibiotic resistant Staphylococcus aureus infections are provided comprising ?-lactam antibiotics, as well as a hyaluronic acid binding peptide. The antibiotics include cephalosporins as well as the ?o?-? lactam antibiotic vancomycin. The methods provide administering the composition to the subject in an amount effective to reduce or eliminate the infection.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: September 5, 2017
    Inventors: Laura Saward, Xiaobing Han, George G. Zhanel
  • Patent number: 9730984
    Abstract: The present disclosure relates to a composition for treating and preventing an rheumatoid arthritis, wherein the composition containing a peptide comprising amino acid sequence of SEQ ID NO: 1, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof. According to the present invention, provided is a composition for prevention or treatment of rheumatoid arthritis having a superior effect of treating and preventing rheumatoid arthritis with minimized side effect.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: August 15, 2017
    Assignee: GEMVAX & KAEL CO., LTD.
    Inventor: Sang Jae Kim
  • Patent number: 9683026
    Abstract: Compositions and methods relating to WSX-1 and p28 (IL-30) are provided. In particular, methods of treating inflammatory conditions in mammalian subjects using various WSX-1, p28, EBI3, and gp130 polypeptides and complexes or moieties that bind to or modulate activity of such complexes are described. Isolated or recombinant complexes including soluble WSX-1 or gp130 polypeptides, isolated or recombinant WSX-1 fusion proteins, and isolated or recombinant p28 fusion proteins are also described.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: June 20, 2017
    Inventors: Christopher A. Hunter, Jason Scott Stumhofer
  • Patent number: 9676822
    Abstract: Disclosed is an oligopeptidic compound capable of interacting with proliferating cell nuclear antigen (PCNA), wherein the compound comprises a PCNA interacting motif which is: (SEQ?ID?NO.?28) [K/R]-[F/Y/W]-[L/I/V/A/M]-[L/I/V/A/M]-[K/R]; wherein the oligopeptidic compound has 9-70 subunits and comprises at least one signal sequence, wherein the signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence and wherein in said compound a PCNA interacting motif is N-terminal to a signal sequence. Also disclosed are methods of treatment of a disorder or condition where it is desirable to inhibit the growth of cells, or a method of treatment which involves cytostatic therapy, or a method of treatment of inflammation said method comprising administering the oligopeptidic compound to a subject in need thereof.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: June 13, 2017
    Inventors: Marit Otterlei, Per Arne Aas, Emadoldin Feyzi
  • Patent number: 9657072
    Abstract: The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: May 23, 2017
    Assignees: Centre National De La Recherche Scientifique, Immupharma France SA
    Inventors: Sylviane Muller, Jean-Paul Briand, Robert H. Zimmer
  • Patent number: 9644001
    Abstract: A vector that includes a cell-penetrating peptide linked to a therapeutic agent. The therapeutic agent can be a cytotoxic agent, an anti-viral agent, an anti-bacterial agent, or an anti-parasitic agent.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 9, 2017
    Assignees: Universite Pierre Et Marie Curie (Paris 6), Institut Curie
    Inventors: Angelita Rebollo Garcia, Fariba Nemati, Didier Decaudin, Jeronimo Bravo Sicilia, Jesus Maria Fominaya Gutierrez
  • Patent number: 9617302
    Abstract: The invention relates to a peptide compound and its pharmaceutical composition for inhibiting platelet aggregation and preventing/treating thrombogenic diseases. The invention develops pentapeptides and hexapeptides derived from snake venom C-type lectin-like proteins (CLPs) fragments, which can inhibit platelet aggregation and have antithrombotic activity without hemorrhagic tendency. Accordingly, they can be used as potential agents for the prevention and therapy of thrombogenic diseases.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: April 11, 2017
    Inventors: Tur-Fu Huang, Chien-Hsin Chang, Ching-Hu Chung
  • Patent number: 9617606
    Abstract: The present invention provides an oligonucleotide for HIV detection including a base sequence which is at least 80% identical to a base sequence composed of 10 or more continuous bases in a base sequence represented by SEQ ID NO. 1 or 6, and an HIV detection kit and an HIV detection method that uses the oligonucleotide for HIV detection.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: April 11, 2017
    Assignee: Japan Science and Technology Agency
    Inventors: Taketoshi Mizutani, Aya Ishizaka
  • Patent number: 9597362
    Abstract: The disclosure relates to the live cultures of probiotic bacteria to treat infectious diseases in humans and animals. Food-grade or non-pathogenic cultures are used to treat localised infections.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: March 21, 2017
    Inventors: Paul Ross, Colin Hill, William Meaney
  • Patent number: 9580472
    Abstract: Anti-microbial peptides and methods of use are provided.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: February 28, 2017
    Assignee: Board of Regents of the University of Nebraska
    Inventor: Guangshun Wang
  • Patent number: 9572900
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: February 21, 2017
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 9567368
    Abstract: Peptides that increase melanin synthesis are provided. These peptides include pentapeptides YSSWY (SEQ ID NO: 1), YRSRK (SEQ ID NO: 2), and their variants. The peptides may activate the enzymatic activity of tyrosinase to increase melanin synthesis. The pharmaceutical, cosmetic, and other compositions including the peptides are also provided. The methods of increasing melanin production in epidermis of a subject are provided where the methods include administering compositions comprising an amount of one or more peptides effective to increase the melanin production. The methods also include treating vitiligo or other hypopigmentation disorders with compositions including one or more peptides.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: February 14, 2017
    Assignee: Escape Therapeutics, Inc.
    Inventors: Basil M. Hantash, Anan Abu Ubeid
  • Patent number: 9562066
    Abstract: The present invention relates to methods of treating or reducing the risk of necrotizing enterocolitis (NEC) in an infant comprising orally administering an effective amount of a CpG-ODN. It is based, at least in part, on the results of experiments in which orally administered CpG-ODNs were observed to reduce the histopathology and markers of inflammation in a murine model for NEC. The present invention further provides for oral formulations of CpG-ODN for administration to infants.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: February 7, 2017
    Assignee: University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventor: David J. Hackam
  • Patent number: 9562075
    Abstract: The invention relates to the use of a peptide derived from HPV-E2, E6 and/or E7 protein for the manufacture of a medicament for the treatment or prevention of an HPV related disease, wherein the medicament is for intradermal administration.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: February 7, 2017
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • Patent number: 9482676
    Abstract: The present invention provides a method for detecting idiopathic interstitial pneumonia, which comprises measuring the expression level of a periostin gene or the amount of a periostin protein in a biological sample. Thereby, a method for detecting idiopathic interstitial pneumonia using a marker is provided.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 1, 2016
    Inventors: Kenji Izuhara, Shoichiro Ohta, Hiroshi Shiraishi, Hisamichi Aizawa, Tomoaki Hoshino, Masaki Okamoto
  • Patent number: 9476033
    Abstract: The present invention concerns an antigenomic RNA of Newcastle Disease virus (NDV) carrying one or more foreign genes inserted before NP gene, between P and M genes, and/or between HN and L genes. The invention is also directed toward a cDNA encoding a recombinant antigenomic RNA having one or more foreign genes inserted according to the invention, a cell containing the cDNA, a plasmid comprising the cDNA, a cell containing the plasmid, a cell containing the recombinant antigenomic RNA, and a recombinant NDV containing the recombinant antigenomic RNA of the invention, such as a recombinant NDV carrying one or more foreign genes recovered from transcription of the cDNA or the plasmid in a competent cell. The recombinant NDV carrying the one or more foreign genes can be used as a vaccine or vaccine vector.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: October 25, 2016
    Assignee: The University of Maryland, College Park
    Inventors: Siba K. Samal, Zhuhui Huang
  • Patent number: 9464112
    Abstract: Provided are small peptide fragments derived from the NF-?B p65 subunit and a pharmaceutical or cosmetic composition comprising the same. The peptides have a NF-?B inhibitory activity, through controlling the transcription-activation of NF-?B. The peptides inhibit the expressions of pro-inflammatory mediators, which are induced by NF-?B, and also inhibit the transmigration of leukocytes, thereby exhibiting an anti-inflammatory activity. Especially, the peptides have excellent inhibitory activities against dermatitis and skin aging. And also, the peptides inhibit base membrane invasion of cancer cells, thereby exhibiting an inhibitory activity against the growth and/or metastasis of cancer cells.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: October 11, 2016
    Inventors: Jang-Hee Hahn, Chang-Seo Park, In-Young Ko, Byong-Ik Chun, Byoung-Chul Kim
  • Patent number: 9447145
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: September 20, 2016
    Assignee: Trinity Therapeutics, Inc.
    Inventors: Neil M. Bodie, Elliot Altman
  • Patent number: 9433667
    Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: September 6, 2016
    Assignee: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Gentao Liu, Keith L. Black
  • Patent number: 9314516
    Abstract: What is described is a novel genetic screen, involving recombinant technology and class I antigen cross-presentation, to search for supraoptimal superagonists of the 27L MART-1 mutant selecting for single amino acid substitution mutants of 27L that activate human antigen-specific CTL clones recognizing the wild-type MART-126-35 epitope. Three novel mutant epitopes are identified with superagonist properties that are functionally superior to 27L. The ability of a given analog to act as superagonist varies among patients. Also described is the use of methods to establish panels of potential superagonist APLs to individualize tumor peptide vaccines among patients. The methodology is replicated to identify APL to NY-ESO-1157-165 and NY-ESO-1157-170 tumor epitopes. A general method is described that is useful to produce a tumor vaccine to any tumor epitope.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: April 19, 2016
    Inventors: Cassian Yee, Yongqing Li, C. Siddiq Abdul-Alim
  • Patent number: 9273111
    Abstract: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterized by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: March 1, 2016
    Assignees: Universite de Lorraine, Bristol-Myers Squibb
    Inventors: Gilbert Faure, Sebastien Gibot, Paola Panina, Nadia Passini
  • Patent number: 9260476
    Abstract: Disclosed are RNA targeting compounds, methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: February 16, 2016
    Assignee: The Research Foundation for The State University of New York
    Inventor: Matthew David Disney
  • Patent number: 9221881
    Abstract: The invention relates to new peptides and to their use in the diagnosis of celiac disease.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: December 29, 2015
    Assignee: Charité-Universitätsmedizin Berlin
    Inventor: Karl Skriner
  • Patent number: 9206234
    Abstract: The invention provides a method of making a peptide comprising the amino acid sequence WDLYFEIVW (SEQ ID NO: 322) or a variant thereof, the method comprising (a) coupling the C-terminal amino acid of the peptide to a cleavable linking moiety bonded to a solid phase support material, wherein the alpha-amino group of the C-terminal amino acid that is to be coupled bears an Fmoc protecting group; (b) removing the Fmoc protecting group from the C-terminal amino acid that is coupled to the linking moiety; (c) successively coupling Fmoc-protected amino acids to the C-terminal amino acid, with attendant cleavage of the Fmoc protecting group prior to each successive amino acid addition, thereby producing an amino acid sequence bearing side chain protecting groups; and (d) removing the side chain protecting groups and cleaving the peptide from the solid phase support material.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: December 8, 2015
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • Patent number: 9193765
    Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: November 24, 2015
    Inventors: Takuya Tsunoda, Ryuji Ohsawa
  • Patent number: 9156906
    Abstract: In one embodiment, the invention provides glycopeptides (or carbohydrate-peptide conjugates) comprising TACAs that direct against (e.g., bind specifically to) cytotoxic T lymphocytes (CTLs) or helper T cells for, e.g., CTL- or T-helper-based immunotherapy of carcinomas, and methods for making and using the glycopeptides of the invention. In one embodiment, the invention provides novel glycopeptides comprising tumor-derived carbohydrate or tumor-derived epitopes that specifically bind to major histocompatibility (MHC) class I molecules on cytotoxic T lymphocytes (CTLs) or MHC molecules on helper T cells, and methods for using same, e.g., as a vaccine, including a pan-cancer vaccine.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: October 13, 2015
    Inventor: Alessandra Franco
  • Patent number: 9096689
    Abstract: The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: August 4, 2015
    Inventors: Olga Volpert, Yelena Mirochnik
  • Patent number: 9072773
    Abstract: The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide that associates with (e.g., specifically binds to) the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that associate with (e.g., specifically bind to) neurons or nerves and for compositions thereof.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: July 7, 2015
    Inventors: Jesus Gonzalez, Junjie Liu
  • Patent number: 9072709
    Abstract: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: July 7, 2015
    Assignees: The Regents of the University of California, The United States of America Represented by The Department of Veterans Affairs
    Inventors: Samuel S. Murray, Elsa Murray, Jeffrey Wang, Keyvan Behnam
  • Publication number: 20150148302
    Abstract: The present invention relates to compositions, including membrane permeable complexes, comprising a Caspase 2 activation inhibitory peptide having the amino acid sequence AFDAFC as well as methods of using the same for the treatment of neurodegenerative conditions associated with apoptosis in the central nervous system, such as Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's chorea, and Creutzfeld-Jacob disease.
    Type: Application
    Filed: March 7, 2014
    Publication date: May 28, 2015
    Applicant: The Trustees of Columbia University in the city of New York
    Inventor: Carol M. Troy
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar